NRXBF NurExone Biologic Inc.
NurExone Biologic Inc. (NRXBF) is expected to report earnings on November 30, 2026, before the market open. The consensus earnings estimate is a loss of $0.01 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +17.3% since its last earnings release on August 31, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About NurExone Biologic Inc.
NurExone Biologic Inc. is a pharmaceutical company which involved in developing a platform for biologically guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company's principal product includes ExoPTEN. NurExone Biologic Inc. is based in HAIFA, Israel.
Sector
Healthcare
Industry
Biotechnology